BPMC News and Press, Blueprint Medicines Corporation From 06/23/22

Blueprint Medicines Appoints Habib Dable to its Board of Directors PR Newswire CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr...

Citi has downgraded Blueprint Medicines (NASDAQ:BPMC) to Sell from Neutral after the commercial-stage biotech announced on Thursday a shift in the primary endpoint for a pivotal trial designed to evaluate its kinase inhibitor Ayvakit in non-advanced systemic mastocytosis (SM). The swap in mai...

Blueprint Medicines (NASDAQ:BPMC) stock fell ~9% on June 9 after the company said that it will swap the objectives of a key study of its medicine Ayvakit after recommendation from the U.S. Food and Drug Administration (FDA) The company is evaluating Ayvakit (avapritinib) in a t...

Gainers: Bluejay Diagnostics BJDX +29%. DBV Technologies DBVT +12%. Arcellx (ACLX) +10%. Immix Biopharma (IMMX) +10%. AbCellera Biologics (ABCL) +8%. Losers: Precision BioSciences (DTIL) -10%. Blueprint Medicines (BPMC) -9%. Hutchmed (China) (HCM)&...

Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis PR Newswire -- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world ...

Update 12:15pm: Updates shares, adds other potential names benefitting from the deal. Blueprint Medicines (NASDAQ:BPMC) rose 4% after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) c...

Blueprint Medicines (NASDAQ:BPMC) rose 1.2% in premarket trading,  after Bristol Myers (BMY) agreed to acquire Turning Point Therapeutics (TPTX) for over $4B in cash. Stifel said in a note that buy-rated Blueprint (BPMC) came first to mind after Bristol agreed to buy TPTX. Blue...

Jefferies has upgraded Blueprint Medicines (NASDAQ:BPMC) to Buy from Hold as the commercial-stage biotech prepares to report topline data for registration-enabling PIONEER trial for Ayvakit in non-advanced (Indolent) systemic mastocytosis (ISM) in late summer 2022. A rare genetically driven c...

A lot of small biotechs are fantastic buys right now. With Big Pharma sitting on a lot of cash, we might start seeing some smart acquisitions later this year. We asked a trio of contributors to pick the biotechs they're feeling most bullish about as potential buyout candidates in 2022. ...

Blueprint Medicines Corporation (BPMC) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Jenna Cohen - Senior Director and Head of Investor Relations Kate Haviland - Chief Executive Officer Christy Rossi - Chief Operating Officer Philina Lee - Chief Commercial Offic...